Table 1.
Overview of the consumption of tacrolimus, azathioprine, cyclosporin, mycophenolic acid, sirolimus, and everolimus in Montenegro, Finland, Croatia, and Serbia in the period 2009–2019, presented as the number DDD/TID and euros (€).
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | DDD/TID (€**) | ||
| Tacrolimus | MNE | 0.05 (150.25) | 0.05 (144.83) | 0.05 (119.60) | 0.05 (64.40) | 0.06 (130.80) | 0.06 (155.86) | 0.07 (187.47) | 0.09 (187.47) | 0.08 (159.77) | 0.10 (127.72) | 0.11 (127.30) |
| FIN | 0.12 (2,905.00) | 0.13 (2,984.00) | 0.15 (3,427.00) | 0.16 (3,751.00) | 0.14 (2,907.00) | 0.17 (3,524.00) | 0.22 (4,539.00) | 0.24 (4,879.00) | 0.28 (5,639.00) | 0.34 (6,721.00) | 0.39 (7,378.00) | |
| CRO | 0.04 (737.15) | 0.08 (1,334.99) | 0.09 (1,523.85) | 0.12 (1,974.56) | 0.19 (2,160.22) | 0.15 (1,945.35) | 0.18 (2,453.27) | 0.20 (2,577.19) | 0.21 (2,498.61) | 0.24 (2,824.21) | 0.28 (3,341.05) | |
| SRB | 0.04 (1,170.87) | 0.04 (1,222.42) | 0.05 (1,412.10) | 0.05 (1,273.88) | 0.05 (1,187.68) | 0.06 (1,198.76) | 0.07 (1,474.81) | 0.07 (1,488.72) | 0.08 (1,775.78) | 0.10 (1,900.15) | 0.09 (1,679.32) | |
| Azathioprine | MNE | 0.19 (15.09) | 0.19 (13.26) | 0.18 (18.71) | 0.25 (33.63) | 0.25 (33.17) | 0.29 (39.67) | 0.26 (33.21) | 0.31 (33.21) | 0.36 (43.99) | 0.36 (44.23) | 0.36 (43.23) |
| FIN | 1.08 (752.00) | 1.09 (760.00) | 1.19 (851.00) | 1.18 (850.00) | 0.93 (675.00) | 1.25 (904.00) | 1.25 (909.00) | 1.41 (1,029.00) | 1.39 (997.00) | 1.48 (1,078.00) | 1.17 (861.00) | |
| CRO | 0.21 (248.04) | 0.24 (218.35) | 0.29 (242.56) | 0.31 (260.82) | 0.35 (291.37) | 0.36 (295.04) | 0.39 (322.82) | 0.40 (329.99) | 0.41 (333.18) | 0.40 (311.12) | 0.43 (338.84) | |
| SRB | 0.15 (246.00) | – | – | 0.03 (330.64) | 0.03 (455.40) | 0.03 (390.16) | 0.04 (517.92) | 0.03 (389.53) | 0.41 (552.32) | 0.41 (545.47) | 0.48 (634.77) | |
| Cyclosporin | MNE | 0.07 (138.81) | 0.07 (68.96) | 0.08 (97.94) | 0.07 (77.09) | 0.08 (99.32) | 0.07 (82.88) | 0.06 (80.41) | 0.07 (80.41) | 0.06 (71.94) | 0.06 (72.56) | 0.06 (68.16) |
| FIN | 0.45 (8,390.00) | 0.45 (8,293.00) | 0.44 (8,159.00) | 0.43 (8,253.00) | 0.44 (8,020.00) | 0.44 (7,678.00) | 0.44 (7,672.00) | 0.42 (7,051.00) | 0.40 (6,055.00) | 0.40 (4,933.00) | 0.39 (4,744.00) | |
| CRO | 0.12 (1,326.35) | 0.16 (1,603.97) | 0.18 (1,764.67) | 0.17 (1,727.33) | 0.18 (1,570.71) | 0.16 (1,524.78) | 0.18 (1,625.16) | 0.18 (1,560.77) | 0.17 (1,341.99) | 0.16 (1,307.51) | 0.16 (1,276.46) | |
| SRB | 0.05 (970.64) | 0.04 (827.04) | 0.05 (883.56) | 0.06 (861.49) | 0.05 (908.16) | 0.04 (793.86) | 0.05 (676.04) | 0.06 (813.58) | 0.05 (778.28) | 0.05 (737.47) | 0.05 (751.61) | |
| Mycophenolic acid | MNE | 0.10 (217.06) | 0.10 (213.90) | 0.10 (156.56) | 0.10 (144.99) | 0.13 (183.71) | 0.13 (177.50) | 0.14 (193.50) | 0.15 (193.50) | 0.15 (161.99) | 0.15 (124.87) | 0.18 (136.99) |
| FIN | 0.29 (5,420.00) | 0.32 (5,884.00) | 0.32 (5,311.00) | 0.35 (5,338.00) | 0.29 (4,502.00) | 0.34 (5,218.00) | 0.39 (6,031.00) | 0.40 (5,152.00) | 0.43 (4,419.00) | 0.44 (4,577.00) | 0.47 (4,743.00) | |
| CRO | 0.20 (3,144.69) | 0.26 (3,645.52) | 0.30 (4,082.20) | 0.77 (3,636.26) | 1.43 (5,305.57) | 0.43 (5,318.55) | 0.42 (4,022.40) | 0.47 (4,592.25) | 0.44 (4,325.49) | 0.48 (4,611.18) | 0.50 (4,722.74) | |
| SRB | 0.07 (1,793.76) | 0.07 (1,744.48) | 0.08 (1,718.41) | 0.01 (1,115.69) | 0.02 (1,298.67) | 0.02 (1,338.40) | 0.05 (1,016.12) | 0.03 (977.74) | 0.05 (992.90) | 0.08 (1,131.53) | 0.08 (1,127.02) | |
| Sirolimus | MNE | 0.00* (11.08) | 0.00* (8.42) | 0.00* (3.89) | 0.00* (2.31) | – | 0.00* (6.99) | 0.00* (3.60) | 0.00* (3.60) | 0.00* (7.99) | 0.00* (6.19) | 0.00* (7.80) |
| FIN | 0.00* (77.00) | 0.00* (86.00) | 0.00* (88.00) | 0.00* (86.00) | 0.00* (81.00) | 0.00* (91.00) | 0.01 (113.00) | 0.01 (124.00) | 0.01 (149.00) | 0.01 (159.00) | 0.01 (191.00) | |
| CRO | 0.00* (87.51) | 0.00* (82.42) | 0.00* (92.03) | 0.00* (88.65) | 0.01 (86.45) | 0.01 (95.31) | 0.01 (87.68) | 0.01 (93.80) | 0.01 (90.43) | 0.01 (84.79) | 0.00* (74.33) | |
| SRB | 0.01 (214.55) | 0.01 (194.75) | 0.00* (124.27) | 0.00* (94.75) | 0.00* (113.95) | 0.00* (101.26) | – | 0.00* (59.54) | 0.00* (72.22) | 0.00* (85.21) | 0.00* (78.90) | |
| Everolimus | MNE | – | – | 0.00* (12.52) | 0.00* (66.59) | 0.00* (122.63) | 0.00* (179.08) | 0.00* (113.55) | 0.00* (113.55) | 0.00* (144.30) | 0.00* (152.76) | 0.00* (328.61) |
| FIN | 0.00* (29.00) | 0.00* (411.00) | 0.00* (1,191.00) | 0.00* (1,772.00) | 0.00* (2,083.00) | 0.00* (2,180.00) | 0.00* (2,280.00) | 0.00* (1,976.00) | 0.00* (1,865.00) | 0.00* (2,065.00) | 0.00* (1,711.00) | |
| CRO | 0.00* (32.79) | 0.00* (24.73) | 0.00* (20.22) | 0.01 (287.56) | 0.01 (652.68) | 0.02 (1,281.74) | 0.03 (1,589.99) | 0.04 (2,143.63) | 0.05 (2,118.39) | 0.06 (1,914.11) | 0.07 (1,537.37) | |
| SRB | 0.00* (0.55) | 0.00* (3.02) | 0.00* (3.84) | 0.00* (24.25) | 0.00* (44.40) | 0.01 (203.74) | 0.01 (243.50) | 0.01 (279,87) | 0.01 (752.07) | 0.01 (959.97) | 0.01 (1,211.05) |
0.00*, consumption below 0.01%.
**
Cost expressed in euros as actual cost/1000.
MNE, Montenegro; FIN, Finland; CRO, Croatia; SRB, Serbia.